Cover Image
市場調查報告書

美國的不孕治療市場:2016∼2020年

Fertility Market in the US 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 351651
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
美國的不孕治療市場:2016∼2020年 Fertility Market in the US 2016-2020
出版日期: 2016年01月27日 內容資訊: 英文 63 Pages
簡介

預計美國的不孕治療服務市場,2016∼2020年以年複合成長率4.07%擴大。男性或女性的不孕要素佔整體3分之一,剩餘原因不明或者或男性,女性雙方有以上任一原因。

本報告提供美國的不孕治療市場相關調查,不孕的病因,診斷和治療等概要,市場趨勢與到2020年的預測,市場課題,主要供應商趨勢與主要供應商所面臨的市場機會和威脅等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 美國的法律規章方案

第6章 市場情況

  • 市場概要
  • 波特的五力分析

第7章 不孕:概要

  • 病因
  • 症狀
  • 檢驗和診斷
  • 治療

第8章 不孕治療的階段

第9章 ART的成本分析

  • 直接費
  • 間接費

第10章 各類型市場區隔

第11章 推動市場的要素

第12章 促進要素的影響

第13章 市場課題

第14章 促進要素與課題的影響

第15章 市場趨勢

  • 合併、收購的增加
  • 研究開發的增加
  • 新不孕治療診所的成立

第16章 供應商環境

  • 競爭模式
  • 主要消息
  • 合併、收購
  • 授權與聯合
  • 市場佔有率分析
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR8375

About Fertility

Couples with fertility issues are unable to conceive even after regular unprotected coitus (six months if the woman is over age 35). Female or male infertility factors account for one-third of the cases, where a couple is unable to conceive. In the rest of the cases, the cause is either unknown or a combination of both male and female infertility factors.

In males, low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm can lead to infertility. In females, hormonal changes, fallopian tube damage, endometriosis, and cervical abnormalities can lead to infertility. Diagnosing the cause of infertility can be difficult but people with fertility issues have many treatment options depending on the underlying problem.

Technavio's analysts forecast the fertility services market in the US to grow at a CAGR of 4.07% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the fertility treatment market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of fertility drugs and the use of assisted reproductive technology (ART).

The market is divided into the following segments based on treatment type:

  • ART
  • Infertility drugs

Technavio's report, Fertility Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Cellcura
  • CooperSurgical
  • Intramed
  • Ferring Pharmaceuticals
  • Merck

Other Prominent Vendors

  • Abbott Laboratories
  • AbbVie
  • Actavis
  • Apricus Biosciences
  • AstraZeneca
  • Auxogyn
  • Bristol-Myers Squibb
  • Elelixis Diagnostics
  • Eli Lilly
  • EMD Serono
  • IKS International
  • In Vitro Care
  • Invo Bioscience
  • Irvine Scientific
  • IVFtech Aps
  • Life Global
  • Medical Electronic Systems
  • Meditex
  • Novartis
  • Ovascience
  • Pantec Biosolutions
  • Pfizer
  • Sanofi
  • Vivus
  • Xytex Cryo International

Market driver

  • Emergence of ART and acceptance of same-sex marriage
  • For a full, detailed list, view our report

Market challenge

  • High cost of fertility treatment
  • For a full, detailed list, view our report

Market trend

  • Increase in M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Regulatory scenario in the US

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Infertility: An overview

  • Etiology
  • Etiology: Female infertility
  • Signs and symptoms
  • Tests and diagnosis
  • Treatment

PART 08: Stages of fertility treatment

PART 09: Cost analysis of ART

  • Direct cost
  • Indirect cost

PART 10: Market segmentation by type

  • Infertility drugs
  • Fertility drugs market in US
  • ART
  • ART market in US

PART 11: Market drivers

  • Emergence of ART and acceptance of same-sex marriage
  • Increasing success rate of infertility treatment
  • Increase in infertility complications

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of fertility treatment
  • Complications of fertility services
  • Limited reimbursement
  • Minimal regulations

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increase in M&A
  • Rise in R&D
  • Establishment of new fertility clinics

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Licensing and collaborations
  • Market share analysis
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Number of ART procedures in US 2002-2013
  • Exhibit 03: Number of ART procedures in the US by fresh embryo from non-donor oocytes
  • Exhibit 04: Number of ART procedures in the US by thawed embryos from non-donor oocytes
  • Exhibit 05: Fertility services market in US 2015-2020 ($ billions)
  • Exhibit 06: Five forces analysis
  • Exhibit 07: Types of infertility
  • Exhibit 08: Causes of male infertility
  • Exhibit 09: Causes of female infertility
  • Exhibit 10: Stages of fertility treatment
  • Exhibit 11: Segmentation of fertility services market in US by treatment type
  • Exhibit 12: Segmentation of fertility services market in US by treatment type 2015
  • Exhibit 13: Fertility drugs market in US 2015-2020 ($ billions)
  • Exhibit 14: Types of ART
  • Exhibit 15: IVF procedure
  • Exhibit 16: Success rate of IVF
  • Exhibit 17: Infertility rate in US by sex 2010
  • Exhibit 18: Infertility rate in US by age 2002 and 2010
  • Exhibit 19: Different categories of ART in US
  • Exhibit 20: Comparison of fresh and frozen ART cycle
  • Exhibit 21: ART market in US 2015-2020 ($ billions)
  • Exhibit 22: ART procedures and number of infants born in US 2002-2011 (thousands)
  • Exhibit 23: Same-sex married couples in US 2008-2013 (thousands)
  • Exhibit 24: Infertility by reproductive group in US
  • Exhibit 25: Adult Americans with obesity 2012
  • Exhibit 26: Adult Americans with obesity 2030
  • Exhibit 27: Impact of drivers
  • Exhibit 28: Average cost of fertility services in US
  • Exhibit 29: States that require people to have insurance coverage for fertility services
  • Exhibit 30: Impact of drivers and challenges
  • Exhibit 31: Recent M&A
  • Exhibit 32: Number of fertility clinics in US 2010-2014
  • Exhibit 33: CellCura: Key takeaways
  • Exhibit 34: CooperSurgical: Business segmentation by revenue 2014
  • Exhibit 35: IntegraMed: Key takeaways
  • Exhibit 36: Ferring Pharmaceuticals: Key takeaways
  • Exhibit 37: Merck: Business segmentation by revenue 2014
  • Exhibit 38: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 39: Merck: Geographical segmentation by revenue 2014
  • Exhibit 40: Merck: Key drivers in fertility services sector
  • Exhibit 41: Merck: Key takeaways
Back to Top